EBMT 2025 | The potential of improving post-transplant outcomes with cytokine-activated NK-cells
Rémy Duléry, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the potential of using cytokine-activated natural killer (NK) cells after haploidentical stem cell transplantation (SCT) to improve patient outcomes. Recent advances in NK-cell therapy have led to the ability to expand donor-derived NK-cells ex vivo in large numbers, enhance their persistence and efficacy in vivo with cytokine activation, and infuse them post-SCT in relapsed patients or those with high-risk disease. Dr Duléry hopes this approach will be further explored in future clinical trials. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We have recently published a review article on the possibility of using NK cells after haploidentical transplant. So, in this article, we highlight that NK cells have unique abilities to kill tumor cells, and when activated by cytokines, it enhances their potential. It enhances their survival and proliferation. And we now have several clinical trials showing that you can use those cytokine-activated NK cells to treat relapse after haploidentical transplants or also to prevent relapse in case of high-risk disease...
We have recently published a review article on the possibility of using NK cells after haploidentical transplant. So, in this article, we highlight that NK cells have unique abilities to kill tumor cells, and when activated by cytokines, it enhances their potential. It enhances their survival and proliferation. And we now have several clinical trials showing that you can use those cytokine-activated NK cells to treat relapse after haploidentical transplants or also to prevent relapse in case of high-risk disease. It’s been a challenge in the beginning because of the difficulty to expand NK cells, but now I think we have reached the point that we have at least four clinical trials with high expansion of those cytokine-activated NK cells. And we hope it will be further used in the future clinical trials for the benefit of the patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
